Terms ending in 2035
Every in-force patent on Kymab Limited's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,259,880 | Anti-Light Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,512,229 | Synergistic Combinations of OX40L Antibodies for the Treatment of GVHD In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,587,030 | Anti-hOX40L Antibodies, Uses, & Methods In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,868,789 | Synergistic Combinations of OX40L Antibodies for the Treatment of GVHD In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,868,790 | Synergistic Combinations of OX40L Antibodies for the Treatment of GVHD In force · High confidence | Kymab Limited | In force | High confidence | |
| US 10,654,935 | Methods of Treating Sle with ANTI-OX40L Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 10,669,342 | ANTI-OX40L Antibodies and Methods of Treating Graft Versus Host Disease In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,396,550 | Methods of Treating Comprising Administering ANTI-OX40L Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,753,479 | Nucleic Acids Encoding ANTI-OX40L Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,773,175 | Antibodies, Uses & Methods In force · High confidence | Kymab Limited | In force | High confidence | |
| 3 more term ends in 2035 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.